Roche secures Zealand obesity drug candidate for up to $5.3 billion
Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, ...
Data on new Novo Nordisk obesity drug disappoints in trial, shares drop
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...
pharmaphorum1d
BMS completes acquisition of Amylin, AZ buys equal share
It has been announced that following Bristol-Myers Squibb’s (BMS) successful acquisition of Amylin Pharmaceuticals, AstraZeneca (AZ) has made an initial payment of approximately US $3.2 billion ...
pharmaphorum4d
Amylin Pharmaceuticals bought by Bristol-Myers, expanding diabetes alliance with AstraZeneca
Bristol-Myers Squibb Co. has announced it will acquire Amylin Pharmaceuticals for approximately US $5.3 billion in cash. Following the completion of this acquisition, Bristol-Myers Squibb will ...
The Globe and Mail5d
This Top Dividend Stock Just Entered The Weight Loss Market: Is It a Buy?
Instead, this investigational medicine mimics the activity of two hormones: amylin and calcitonin. The former helps regulate blood sugar levels and controls satiety. The latter regulates calcium ...
BioSpace4d
Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option
LEN+TAB+ZAB (LTZ) harbors the potential to be the first long-acting combination treatment regimen with twice-yearly dosing. At CROI 2025, the primary results of a Phase 2 study evaluating the ...